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Severe malaria kills ~660,000 people worldwide annually, the 
greatest burden of mortality occurring in young children.1 Early 
diagnosis and treatment with highly effective antimalarial drugs 
are critical in the management of acute malaria, since most 
deaths occur within the first 24 h of presentation.2,3 Two large 
multicenter randomized controlled trials have demonstrated 
con clusively the superior efficacy of parenteral artesunate (ARS) 
over intravenous (i.v.) quinine in reducing the mortality of severe 
falciparum malaria. ARS resulted in a 35% relative reduction in 
mortality in patients of all ages in the South East Asian Quinine 
Artesunate Malaria Trial study (10 centers in four Asian coun-
tries)4 and 23% in the African Quinine Artesunate Malaria Trial 
study of African children (11 centers in nine African countries).5
Based on these studies, i.v. ARS is now recommended as 
the first-line treatment for severe malaria for adults and chil-
dren worldwide.6 Most guidelines recommend a single dose 
followed by a second dose at 12 h and then every 24 h until 
oral treatment can be tolerated. Although this dosing strategy 
appears efficacious, it is based on clinical trials rather than 
pharmacokinetic (PK)–pharmacodynamic (PD) assessments. 
A recent population PK analysis of ARS and dihydroartemis-
inin (DHA; the active metabolite of ARS) concentrations, after 
intramuscular (i.m.) administration of ARS (i.m. ARS) in Afri-
can children with severe malaria, suggests that DHA expo-
sure is reduced in smaller children (weighing 6–10 kg).7 A 
dosing regimen based on weight bands was found to achieve 
comparable DHA exposure levels in smaller and larger chil-
dren, and indicates that the i.m. ARS for children weighing 
6–10 kg should be between 2.7 and 3.3 mg/kg.7
The life-saving benefit of ARS in severe malaria results 
from its broad stage-specific activity over the 48 h life cycle 
of the parasite in the red blood cell. ARS kills the circulat-
ing ring-stage parasites before they can mature,8,9 thereby 
preventing deaths resulting from microvascular obstruction 
in the vital organs.10–12 Recent reports from South-East Asia 
indicate delayed parasite clearance for patients administered 
oral ARS, signaling the emergence of artemisinin-resistant 
Plasmodium falciparum.13–15 Mathematical modeling of data 
from this region16 suggests that the killing rate of ARS on the 
ring-stage parasites is reduced. This reduction in ring-stage 
killing results in a greater proportion of parasites maturing in 
the erythrocytes, which in turn would lead to more seques-
tration in the capillaries, end organ damage, and ultimately 
death. A possible strategy to overcome this reduction in the 
killing rate of ARS is to administer higher doses or give ARS 
more frequently. However, evidence from a clinical trial con-
ducted in western Cambodia found that patients given 6 mg/
kg of oral ARS daily for 7 days had an increased risk of neu-
tropenia compared with those given 2 or 4 mg/kg.17
Based on evidence of emerging resistance and dose-depen-
dent toxicity of ARS, it is crucial that the recommended dose 
and frequency of i.v. ARS dose is optimized from an under-
standing of the PK-PD relationships. In this study, we have 
compiled the largest dataset (as of May 2014) of ARS and 
DHA concentrations and parasite counts from adults and chil-
dren with severe malaria and treated with i.v. ARS, developed a 
population PK model, identified clinical covariates that explain 
the variability in observed DHA PK profiles, and examined how 
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There are ~660,000 deaths from severe malaria each year. Intravenous artesunate (i.v. ARS) is the first-line treatment in adults and 
children. To optimize the dosing regimen of i.v. ARS, the largest pooled population pharmacokinetic study to date of the active 
metabolite dihydroartemisinin (DHA) was performed. The pooled dataset consisted of 71 adults and 195 children with severe 
malaria, with a mixture of sparse and rich sampling within the first 12 h after drug administration. A one-compartment model 
described the population pharmacokinetics of DHA adequately. Body weight had the greatest impact on DHA pharmacokinetics, 
resulting in lower DHA exposure for smaller children (6–10 kg) than adults. Post hoc estimates of DHA exposure were not 
significantly associated with parasitological outcomes. Comparable DHA exposure in smaller children and adults after i.v. ARS 
was achieved under a dose modification for intramuscular ARS proposed in a separate analysis of children.
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DHA exposure varies with dosing regimens. The association 
between parasitological outcomes and post hoc estimates of 
DHA exposure for each patient was also examined.
reSUltS
clinical details
Data were collected from six studies (five published18–22 and 
one unpublished by WHO, but a subset of this study consist-
ing of 12 Thai patients administered intrarectal ARS (i.r. ARS) 
was published in Simpson et al.23) conducted in Africa and 
Asia, of adults or children with severe or moderately severe 
malaria (table 1). Four subgroup analyses were performed 
because the same set of covariates was not measured in 
each of the six studies. Subgroup 1 involves covariates mea-
sured in all six studies, subgroup 2 includes studies with mea-
sures of respiratory distress, and subgroups 3 and 4 include 
covariates measured only in children and adults, respectively. 
table 2 summarizes the distribution of the covariates.
In subgroup 1, 266 patients aged from 6 months to 65 years 
were included in the analysis, of whom 48% (128/266) had a 
documented fever at presentation. Children were more likely 
to present with anemia (hemoglobin < 5 g/dl; 20/195, 8.3%) 
than adults (2/71, 2.8%; P = 0.12) and have a higher base-
line parasitemia (median (range) 155,099 (397–1,870,264) 
vs. 114,520 (80–1,145,000)/µl whole blood, respectively; 
P = 0.001). A total of nine patients died, and these deaths 
occurred in three of the six studies.19,21,22
Population pharmacokinetic analysis
There was limited ARS concentration data available 
 (Supplementary Figure S1), precluding formal PK model-
ing. Nonlinear mixed-effects (NLME) modeling of the DHA 
concentration data from each study separately (i.e., referred 
to as a meta-analytic approach—see “Methods” for details) 
identified the one-compartment PK model assuming i.v. 
bolus dose administration and additive error on the natural 
log scale as providing an adequate fit to the data. Forest plots 
of study heterogeneity additionally found that the estimates 
of population mean clearance (CL) and volume of distribu-
tion (V) tended to be lower in the second compared with the 
first period of the crossover trials (Supplementary Figure 
S2), which indicates that patients who received i.v. ARS in 
the second period tended to have higher drug exposure. 
The visual predictive checks (VPCs) of the two-level mod-
els and posterior predictive check (analogous to a VPC, see 
Supplementary Information 3) of the three-level Bayesian 
model used to investigate whether modeling between-study 
variability improves the predictive properties of the model 
are presented in Supplementary Figure S3. The posterior 
table 1 Study site, number of patients, study population, study design, and ARS dosing scheme(s) for all routes of ARS administration (i.v., i.r., and i.m.) and 
each study contributing data to the pooled analysis
research  
teama
Study  
site
number of 
patientsb
Study  
population
Study  
design
Dosing  
scheme
Kremsner et al.19 Gabon ITT–182 Children with severe malaria Randomized  
controlled trial
  I:  2.4 mg/kg i.v. at 0, 12, 24, 48, 
and 72 h
Malawi PP–177  II: 4 mg/kg i.v. at 0, 24, and 48 h
Krishna et al.20 Ghana 34 Children with moderately 
severe malaria
Crossover trial   I:  10 mg/kg i.r. at 0 h, 2.4 mg/kg 
i.v. at 12 h
 II:  20 mg/kg i.r. at 0 h, 2.4 mg/kg 
i.v. at 12 h
III:  2.4 mg/kg i.v. at 0 h, 20 mg/kg 
i.r. at 12 h
Nealon et al.22 Gabon 28 Children with severe malaria Crossover trial   I:  2.4 mg/kg i.v. at 0 h, 1.2 mg/kg 
i.m. at 12 h
 II:  2.4 mg/kg i.m. at 0 h, 1.2 mg/kg 
i.v. at 12 h
Maude et al.21 Bangladesh 21 Adults with severe malaria Clinical study       2.4 mg/kg i.v. at 0, 12, 24, 48 h, 
and then every 24 h
WHO23 Bangkok,  
Thailand
48 Adults with moderately  
severe malaria
Crossover trial   I:  2.4 mg/kg i.v. at 0 h, 10 mg/kg 
i.r. at 12 h
 II:  10 mg/kg i.r. at 0 h, 2.4 mg/kg 
i.v. at 12 h
III:  2.4 mg/kg i.v. at 0 h, 20 mg/kg 
i.r. at 12 h
IV:  20 mg/kg i.r. at 0 h, 2.4 mg/kg 
i.v. at 12 h
Davis et al.18 Vietnam 30 Adults with either severe or 
moderately severe malaria
Phase I: clinical study      120 mg/kg i.v. at 0 h
Phase II: randomized  
controlled trial
  I: 120 mg/kg i.v. at 0 and 4 h
  II:  240 mg/kg i.v. infusion over 
4 h at 0 h
ARS, artesunate; i.m., intramuscular; i.r., intrarectal; i.v., intravenous; ITT, intention to treat; PP, per protocol; WHO, World Health Organization.
aResearch teams are referred to by first author of the paper the data were published in or by organization that conducted the study (e.g., WHO). Note 
 superscripts in this column are not footnotes, but references. bNumber reported in published paper or internal WHO report.
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predictive check of the three-level model illustrates that this 
model tends to overpredict the between-patient variability in 
the pooled dataset, whereas the VPCs of the two-level mod-
els indicate that these models capture the between-patient 
variability more accurately. Based on these checks, it was 
decided to proceed with covariate selection without explicitly 
modeling between-study differences.
The covariates in each of the four subgroups (table 2) were 
examined for association with population mean PK param-
eters using stepwise covariate selection (see “Methods” for 
details). Note all models included an allometric function of 
body weight on both the population mean CL and V and an 
additional age maturation function on the population mean CL 
(see Supplementary Information 4), unless otherwise stated. 
Since none of the covariates in subgroups 2–4 were found to 
be associated with the PK parameters (see  Supplementary 
table S1), the following analysis is restricted to subgroup 1. The 
parameter estimates for the final model fitted to the subgroup 
1 data are presented in table 3. In subgroup 1, the population 
mean V for men was estimated to be 14% lower (95% confi-
dence interval (CI): 24–3% lower) compared with women (pop-
ulation mean V for men, 9.9 l and for women, 11.6 l), implying 
that men tend to achieve a higher maximum drug concentration 
(C
max
). However, since the population mean CL was the same 
for men and women, the total drug exposure (area under the 
curve (AUC)) for both sexes should be the same. The between-
patient variability reduced substantially after inclusion of body 
weight as an allometric function on both population mean 
CL and V (from 91–60% for CL and 86–45% for V; change in 
objective function value (ΔOFV) of 245) and an additional age-
related enzyme-maturation effect on CL (decreased to 59%; 
ΔOFV of 9.3), but inclusion of sex did not further reduce the 
between-patient variability (however, ΔOFV of 6.9).
The sensitivity of stepwise covariate model selection to 
the exclusion of patients in period two of the crossover trials 
was also examined (table 3). The exclusion of these patients 
resulted in stepwise covariate model selection identifying 
hemoglobin and body temperature to be associated with the 
population mean CL, in addition to the association between 
sex and population mean V. In patients receiving i.v. ARS at 
baseline, CL was decreased by 4% per unit (g/dl; 95% CI: 
6% decrease to 1% decrease) increase of hemoglobin and 
increased by 7.0% per unit (°C; 95% CI: 2% increase to 12% 
increase) increase in body temperature. VPCs of the final 
model fitted to the dataset including patients in period two 
of the crossover trials, and excluding these patients indicate 
these models exhibit no model misspecification (Figure 1).
The simulation of DHA exposure after an i.m. ARS dose 
of 2.4 mg/kg described in Hendriksen et al.7 found that DHA 
exposure for smaller children (6–10 kg) was lower than that 
in larger children (21–25 kg); an adjusted dose regimen was 
found to rectify this difference. To examine whether DHA 
exposure after i.v. ARS, administered as the standard 2.4 mg/
kg dose or  according to the proposed weight-band dose regi-
men in Hendriksen et al.7 , exhibits a similar relationship with 
body weight, we replicated the Hendriksen et al.7  simulation 
using our final population PK model. DHA exposures (area 
under the curve from 0 to 12 h (AUC0–12h) h × ng/ml) after 
the standard 2.4 mg/kg dose were simulated at each body 
weight level (1,000 simulations each at 1 kg intervals from 
6 to 25 kg; see Supplementary Information 1 for details). 
Children with body weight between 6 and 10 kg showed a 
reduction in geometric mean DHA exposure of 13.7% (95% 
CI: 11.7–15.6%; P < 0.001) compared with children with 
body weight between 21 and 25 kg. The median (25th to 75th 
percentile) DHA exposure following a dose of 2.4 mg/kg was: 
2,077 (1,403–3,124) h × ng/ml in the 6–10 kg patients; 2,127 
(1,442–3,063) h × ng/ml in the 11–15 kg patients; 2,122 
(1,443–3,094) h × ng/ml in the 16–20 kg patients; and 2,426 
(1,669–3,517) h × ng/ml in patients 21–25 kg.
The results were consistent with those presented in 
 Hendriksen et al.7 and suggest that smaller children need 
higher weight-adjusted doses of i.v. ARS to attain DHA 
table 2 Study populations and distribution of baseline demographic, clinical, 
and laboratory characteristics of children and adults examined in each of the 
four subgroups
Subgroup 1: studies 1–6
Population
children (N = 195) Adults (N = 71)
Age (years) 3.47 (0.57–9.26) 24 (16–65)
Weight (kg) 13 (6–29) 50 (33–75)
Male (%) 52 58
Temperature (°C) 38 (35–40.9) 38.3 (34.2–40.4)
Parasitemia (/µl of blood) 155,099  
(397–1,870,264)
114,520  
(80–1,145,000)
Hemoglobin (g/dl) 8.5 (2.4–13.40) 10.3 (2.9–17)
Subgroup 2: studies 1–5 children (N = 192) Adults (N = 63)
Pulse rate (beats/min)a 140 (80–219) 96 (41–141)
Respiratory rate  
(breaths/min)a
40 (19–80) 24 (20–42)
Subgroup 3: studies 1–3 children (N = 191)
Plasma glucose (mg/dl) 5.5 (0.7–16.71)
BCS ≤ 2 (%) 82.7 (158/191)
Subgroup 4:  
studies 4 and 5 Adults (N = 50)
Hemoglobin (g/dl) 10.55 (2.9–17)
Potassium (mmol/l) 3.65 (2.6–5.1)
Chloride (mmol/l) 102.5 (87–117)
Sodium (mmol/l) 134 (118–148)
Albumin (g/dl) 3.5 (2.1–5.7)
Total bilirubin (µmol/l) 2 (0.46–35.8)
ALT (IU/l) 37 (7–194)
AST (IU/l) 65 (13–349)
ALP (IU/l) 37 (9–314)
WBC count (103 cells/mm3) 7.1 (2.3–12,700)
Neutrophils (% units) 62.95 (30–91)
Lymphocytes (% units) 24.15 (4–48)
Monocytes (% units) 4 (1–27.3)
Creatinine (mg/dl) 1.22 (0.65–6.4)
Blood urea nitrogen (mg/dl) 27.5 (6–154.4)
Plasma lactate (mg/dl) 3.5 (1.2–9.7)
GCS < 11 (%) 46.2 (6/13)
Data are given as median (range) or % (number/frequency).
Studies: 1 = Kremsner et al.19, 2 = Krishna et al.20, 3 = Nealon et al.22,  
4 = Maude et al.21, 5 = WHO23, and 6 = Davis et al.18.
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate 
transaminase; BCS, Blantyre coma score, % patients with BCS ≤ 2; 
GCS, Glasgow coma score, % patients with GCS < 11 (37 missing values); 
WBC, white blood cell.
aPulse rate and respiratory rate missing for a total of 8 adults and 3 children.
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exposures similar to children with higher body weights. The 
adjusted dosing regimen proposed in Hendriksen et al.7 
for i.m. ARS appears to be applicable to i.v. ARS, as it results 
in similar exposures in all weight bands after the first dose of 
i.v. ARS (Figure 2).
A similar simulation was performed for patients older 
than 16 years and weighing between 33 and 75 kg (see 
 Supplementary Information 1 for details). The lower panel 
of Figure 2 indicates that DHA exposure after the standard 
2.4 mg/kg dose in patients weighing between 33 and 76 kg is 
comparable to DHA exposures achieved by children receiving 
the adjusted dosing regimen proposed in Hendriksen et al.7 
(Figure 2, upper panel, red).
Association between post hoc individual PK estimates 
and PD measures
The PD analysis was restricted to the 142 patients receiving 
a dose of 2.4 mg/kg i.v. ARS at baseline. The median parasite 
clearance half-life (time needed for parasitemia to reduce by 
half)24 was 3.1 h (interquartile range: 2.4–3.8; range: 0.9–6) 
with 25% (14/55) of patients clearing 90% of their base-
line parasitemia by 12 h (PC90 at 12 h). Although none of 
the post hoc PK estimates were associated with the parasite 
clearance half-life, an association between post hoc DHA V 
and PC90 at 12 h was found (table 4)—a doubling of V was 
associated with a 0.28-fold decrease in the odds of PC90 
at 12 h (95% CI: 0.07–1.11; P = 0.07). Since many patients 
did not have parasite measurements recorded at 12 h, we 
performed a sensitivity analysis where we imputed parasite 
count at 12 h for patients with at least three parasite counts 
recorded in the first 24 h, including one of these measure-
ments post 12 h (see “Methods,” subsection “Pharmaco-
dynamic measures” for details of imputation). Imputation 
allowed PC90 at 12 h to be calculated for an additional 53 (for 
a total of 108) of the 142 patients. Our findings in table 4 did 
not change materially on inclusion of the additional imputed 
table 3 Parameter estimates of the final model describing the population pharmacokinetics of dihydroartemisinin in all severe malaria patients and for the 
 subpopulation of patients who only received i.v. ARS at baseline
All severe malaria patients Only received i.v. ArS at baseline
Number of samples 1,014 740
Number of patients 266 223
Population estimatea (%RSE) (95% CI)b Population estimatec (%RSE) (95% CI)b
Fixed effects
  Population mean CL (l/h) 13.0 (4.42) (11.9,14.21) 12.9 (4.97) (11.7,14.3)
  βCL,HB n/a −0.04 (36.22) (-0.06,-0.01)
  βCL,TEMP n/a 0.07 (37.47) (0.02,0.12)
  Population mean V (L) 11.56 (5.05) (10.4,12.8) 11.66 (5.67) (10.5,13.1)
  βV,MALE −0.14 (39.1) (−0.24,−0.03) −0.15 (35.03) (−0.25,−0.04)
Random-effect SD and correlation (cor)
  SD of ηCL(ωCL) 0.59 (7.72) (0.51,0.67) 0.55 (7.40) (0.48,0.63)
  SD of ηV (ωV) 0.44 (9.69) (0.35,0.51) 0.42 (12.02) (0.31,0.51)
  cor between ηCLand ηV (ρCL,V) 0.61 (10.49) (0.48,0.73) 0.60 (10.76) (0.47,0.72)
Residual SD (year(s) study was conducted)
  σ1 (2007–2008) 0.34 (28.5) (0.13,0.49) 0.35 (28.99) (0.14,0.52)
  σ2 (1996) 0.36 (19.39) (0.21,0.50) 0.35 (27.68) (0.13,0.52)
  σ3 (2000–2001) 0.43 (22.59) (0.24,0.64) 0.44 (23.79) (0.25,0.65)
  σ4 (2006–2007) 0.36 (16.5) (0.24,0.48) 0.37 (17.06) (0.24,0.49)
  σ5 (1996) 0.30 (14.41) (0.23,0.39) 0.33 (23.38) (0.21,0.50)
  σ6 (1997) 0.27 (18.07) (0.15,0.35) 0.27 (17.89) (0.15,0.36)
Post hoc estimatesd
  CL (l/h/kg) 0.76 (0.29–2.19) 0.76 (0.36–2.07)
  V (l/kg) 0.66 (0.37–1.54) 0.66 (0.43–1.55)
  t1/2 (h) 0.63 (0.27–1.45) 0.63 (0.26–1.35)
  C
max
 (ng/ml) 2,946.6 (1,148.13–6,501.33) 3,053.44 (1,155.01–6,312.63)
  AUC0–12h (h × ng/ml) 2,560.3 (799.58–8,525.76) 2,609.83 (851.26–7,910.63)
βCL,HB, fractional change in population mean CL for a unit (g/dl) increase in hemoglobin from the median (8.8 g/dl); βCL,TEMP, fractional change in population mean 
CL for a unit (°C) increase in temperature from the median (38.2 °C); βCL,SEX, fractional change in population mean V for males compared to females; σi, residual 
standard deviation for study i = 1 (Kremsner et al.19), 2 (Krishna et al.20), 3 (Nealon et al.22), 4 (Maude et al.21), 5 (WHO23), 6 (Davis et al.18); AUC0–12h, area under 
the concentration–time curve from time point 0 to 12 h; ARS, artesunate; CI, confidence interval; C
max
, maximum concentration; CL, DHA clearance (l/h); DHA, 
dihydroartemisinin; PK, pharmacokinetic; t1/2, terminal elimination half-life; V, DHA volume of distribution (l).
aFor the analysis including patients who received i.v. ARS in period two of the crossover trials, the population mean clearance (CL) and volume (V) values are for 
a female patient weighing 15 kg. bCalculated by nonparametric bootstrap method of PK model (“all severe malaria patients”: n = 893 successful iterations out of 
1,000; “Only received i.v. ARS at baseline”: n = 800 successful iterations out of 1,000). Relative standard error (%RSE) is calculated as 100 × (bootstrap standard 
error of estimate/parameter estimate). 95% CI is the 2.5th–97.5th percentiles of the bootstrap estimates. cFor the analysis excluding patients that received 
 i.v. ARS in period two of the crossover trials the population mean clearance (CL) and volume (V) values are for a female patient weighing 15 kg, with  hemoglobin 
levels of 8.8 g/dl and a body temperature of 38.2 °C. dPost hoc estimates are displayed as median values and 2.5th–97.5th percentiles of empirical Bayes 
 estimates. The eta-shrinkage for the “all severe malaria patients” analysis was 8% for CL and 19% for V, and the epsilon-shrinkage was 22%. The eta-shrinkage 
for the “only received i.v. ARS at baseline” analysis was 10% for CL and 23% for V, and the epsilon-shrinkage was 25%.
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PC90 at 12 h (e.g., odds ratios after inclusion of imputed 
PC90 at 12 h were: 1.07 for clearance; 0.38 for volume; 0.77 
for AUC0–12h; and 2.14 for Cmax).
DIScUSSIOn
In the present study, a population PK analysis of the largest 
pooled dataset of DHA drug concentrations to date from severe 
malaria patients has been performed. A one-compartment PK 
model provided the best fit to the pooled DHA concentration–
time data from three studies of nonpregnant South-East Asian 
adults and three studies of African children. Body weight was 
found to be the key covariate influencing the PK of DHA. No 
correlation between the post hoc individual estimates reflecting 
DHA drug exposure and the PD outcomes (parasite clearance 
half-life and PC90 at 12 h) was observed.
The ARS PK data were not modeled because many of 
the ARS concentrations were below the level of detection 
as early as 2 and 4 h post i.v. ARS administration. This is 
a function of study design as the half-life of ARS is much 
shorter than this, while prevention of ex vivo metabolism of 
ARS to DHA after sample collection by using an enzyme 
(esterase) inhibitor such as fluoride was not done in most 
studies. A 100% conversion of ARS into the metabolite, DHA, 
was assumed (i.e., DHA is the sole metabolite of ARS).18 This 
was thought reasonable because the maximum concentra-
tion of DHA occurred shortly (i.e., median 0.5 min) after i.v. 
ARS administration for a study with rich and early sampling 
within the first hour.22 A limitation of not being able to model 
the ARS PK data, and additionally, assuming 100% conver-
sion of ARS to DHA, is overprediction of maximum DHA con-
centrations. However, the VPC demonstrated that the model 
captured the DHA concentration data adequately. Of note, a 
moderate correlation between the post hoc individual CL and 
V estimates was observed. Such a correlation is not typically 
observed for drugs administered i.v. and may be an artifact of 
not modeling the conversion of ARS into DHA (e.g., using a 
parent-metabolite model).
The individual DHA PK datasets comprising the pooled data-
set ranged in sample size from 6 to 157 patients and were of 
homogenous sample populations. Collectively, there were 266 
or 223 patients, depending on whether patients in the second 
period of the crossover trials were included or excluded from the 
analysis, providing reasonable statistical power to identify key 
patient characteristics. There were a number of study-specific 
characteristics that could potentially be sources of between-
study variability: criteria used to diagnose severe malaria var-
ied, patients with severe and moderately severe malaria were 
included; study design, crossover and parallel designs; sample 
preparation and measurement of variables (e.g., drug concen-
tration, parasite counts, and clinical variables)25,26 were likely 
to be inconsistent across studies due to differences between 
sample preparation, preassay extraction, drug assays, and 
technicians. Our examination of between-study heterogeneity 
revealed that DHA exposure tended to be higher in the second 
Figure 1 Visual predictive checks (VPCs) of final models fitted to (a) 
the PK dataset including patients in period two of the crossover trials 
(total n = 266) and (b) excluding patients in period two of the crossover 
trials (total n = 223). In the upper panel, the solid black circles are the 
observed log
e
 DHA plasma concentration (ng/ml) above the respective 
limit of quantification for each study (see Supplementary table S4), 
and the following are plotted for bins across the independent variable 
time: 50th (solid black line), 2.5th, and 97.5th (dashed black lines) 
percentiles of the observed concentrations; and simulation-based 
95% confidence intervals for the predicted 50th (pink region), 2.5th, 
and 97.5th (blue regions) percentiles. In the lower panel, the solid 
black line is the observed fraction of DHA concentrations (at each 
time point of sample collection) below quantification limit (BQL), and 
the blue region is the simulation-based 95% confidence interval for 
the predicted fraction of BQL DHA samples. DHA, dihydroartemisinin; 
PK, pharmacokinetic.
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period of the crossover trials (i.e., after patients have received 
two antimalarial treatments) compared with period one 
 (following an initial treatment). Reduced parasitemia at the time 
of i.v. ARS administration in period two of the crossover trials 
(~12 h) does not appear to explain this finding; baseline para-
sitemia was not found to be statistically significantly associated 
with either of the population mean PK parameters in either the 
analysis including or excluding patients in period two of the 
crossover trials. Evidence of this increase in DHA exposure 
during convalescence was also seen in previous published 
PK analyses of the individual studies included in our pooled 
analyses.20,22,23 Conversely, DHA exposure following oral ARS 
in patients with uncomplicated malaria has been observed 
to decrease during convalescence.27,28 In the acute phase of 
severe malaria, parasite-mediated drug decomposition may 
occur. Another possible contributor is that greater hemolysis 
in the acute phase of severe malaria may result in greater ex 
vivo decomposition (differentially affecting lower drug concen-
trations) and artifactually accelerating the apparent decline 
in plasma concentrations26 unless samples are collected into 
tubes containing enzyme (esterase) inhibitors. Interestingly, 
our pooled analysis revealed that despite improvements in the 
assay methodology to measure plasma drug concentrations, 
improving from earlier (1996–2001, mostly high-performance 
liquid chromatography) to later studies (2006–2008, liquid 
chromatography–mass spectrometry), little change in the mag-
nitude of the within-patient variability was observed (residual 
error: ~35%).
Median (range) post hoc estimates of DHA C
max
, AUC0–12h h 
× ng/ml, and elimination half-life (t1/2) derived from our pooled 
PK model (2,946 ng/ml (1,148–6,501); 2,560 h × ng/ml (799–
8,525); and 0.63 h (0.27–1.45), respectively) are consistent 
with those from the six individual pooled studies (medians 
range from 1,592—3,011 ng/ml for C
max
; 923–2,541.2 h × 
ng/ml for AUC; 0.33–0.67 h for t1/2) and an additional study 
of i.v. ARS in 14 Ugandan adults (median C
max
 3,140; AUC: 
3,492 h × ng/ml; t1/2: 1.31 h).29 Additionally, DHA PK summary 
measures from studies of ARS administered i.v. to healthy 
adult volunteers (medians range from 1,286—1,507 ng/ml for 
C
max
; 1,850 h × ng/ml for AUC; 0.88–1.15 h for t1/2) and adults 
with uncomplicated malaria (medians range from 2,648—
2,758 ng/ml for C
max
; 2,377–2,872 h × ng/ml for AUC; 0.67–
0.98 h for t1/2) reviewed in Morris et al.30 are also contained in 
the range of post hoc estimates derived from our pooled PK 
model. There is evidence that lower maximum concentrations 
for DHA are achieved after i.m. administration compared with 
i.v. administration, but estimates of DHA exposure are gener-
ally similar due to the high bioavailability and rapid absorp-
tion of i.m. ARS.7,30 In a recent study of i.m. ARS in African 
children with severe malaria, the median (range) estimates 
of DHA C
max
, AUC, and t1/2were 547 ng/ml (284–890), 890 h 
× ng/ml (297–2,510), and 0.427 h (0.145–1.18), respectively, 
lower than those derived from our pooled PK model for DHA 
after i.v. ARS.7
All covariates were deemed important a priori, and only age, 
body weight, sex, body temperature, baseline parasitemia, and 
table 4 Estimates of association between the pharmacodynamic outcomes, parasite clearance half-life, and PC90 at 12 h, with the post hoc estimates of DHA 
clearance, volume of distribution, area under the curve (AUC0–12h), and maximum concentration (Cmax) derived from the final model fitted to the PK data from 
patients who received 2.4 mg/kg of i.v. ARS at baseline
PK parametera
Parasite clearance half-life (h) (N = 115) Pc90 at 12 h (N = 55)
Mean 
differenceb,d
95% cI P 
value
Odds 
ratioc,d
95% cI P 
value
DHA clearance (log2 l/h) 0.38 −0.32, 0.39 0.83 1.01 0.36, 2.56 0.98
DHA volume (log2 l) −0.10 −0.52, 0.33 0.65 0.28 0.07, 1.11 0.07
DHA AUC0-12h (log2 h × ng /ml) −0.17 −0.53, 0.19 0.34 0.86 0.30, 2.44 0.78
DHA C
max
 (log2 ng/ml) −0.12 −0.61, 0.37 0.62 3.31 0.77, 14.15 0.11
ARS, artesunate; CI, confidence interval; DHA, dihydroartemisinin; PK, pharmacokinetic.
aPost hoc estimates of clearance, volume of distribution, AUC0-12h, and Cmax were log2 transformed. bMean difference: estimated change in population mean 
parasite clearance half-life for a doubling of post hoc estimate of DHA clearance, volume, AUC0–12h, or Cmax. cOdds ratio: estimated relative change in odds of 
clearing 90% of baseline parasitemia by 12 h for a doubling of post hoc estimate of DHA clearance, volume, AUC0–12h, or Cmax. dAll regression analyses were 
adjusted for age (continuous; years), weight (continuous; kg), sex (male = 1; female = 0), and baseline parasitemia (continuous; log
e
 transformed).
table 5 Sampling times for ARS/DHA concentrations and parasitemia measurements
research team ArS/DHA Parasitemia
Kremsner et al.19 2 samples/patient taken from timesa 0.083, 0.167, 0.25,  
0.5, 1, 2, 4, and 6 h
0, 6, 12, 18, and 24 h and then every 6 h until there were two consecutive 
negativeb slides
Krishna et al.20 0, 0.25, 0.5, 1, 1.5, 2, 4, 8, and 12 h 0, 4, 8, 12, 16, 20, and 24 h and then every 4 h until there were two  
consecutive negativeb slides
Nealon et al.22 0, 0.017, 0.05, 0.1, 0.167, 0.25, 0.75, 1.5, 2, 4, 8, and 12 h 0, 4, 8, 12, 16, 20, and 24 h and then every 6 h until there were two  
consecutive negativeb slides
Maude et al.21 0, 0.167, 0.5, 1, 2, and 4 h 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 h and then every 6 h until parasite 
clearance
WHO23 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, and 12 h 0, 6, 12, 18, and 24 h and then every 6 h until parasite clearance
Davis et al.18 0, 0.083, 0.117, 0.15, 0.2, 0.25, 0.33, 0.75, 1.5, 2, 3,  
and 4 h
0, 0.5, 1, 2, 3, 4, 6, 8, 12, 18, and 24 h and then every 6 h until parasite 
clearance
ARS, artesunate; DHA, dihydroartemisinin; WHO, World Health Organization.
aPatients randomly allocated to one of eight different sampling groups where each sampling group has two time points (e.g., group 1–5 min, 2 h post first dose). 
bNegative slide defined as number of circulating parasitized blood cells below the threshold of detection.
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hemoglobin were available for all six studies. Subgroup analy-
ses were performed to investigate the other covariate effects, 
such as many of the laboratory variables (e.g., bilirubin) that 
were only measured in adults, thereby limiting our statistical 
power to detect PK–covariate relationships. The most signifi-
cant covariate identified in our pooled PK analysis of adults and 
children was body weight. This finding has also been reported 
in other population PK studies of oral, i.r., and i.m. ARS in pedi-
atric7,28,31 and mixed adult–pediatric populations.23 DHA expo-
sure predicted from our pooled PK model after the standard 
2.4 mg/kg dose of i.v. ARS was found to be lower for smaller 
children (6–10 kg) than that for larger children and adults 
(≥25 kg), similar to findings in Hendriksen et al.7 for DHA expo-
sure predicted after the standard 2.4 mg/kg dose of i.m. ARS. 
The weight-band dosing regimen recommended in Hendriksen 
et al.7 for i.m. ARS is also predicted to improve DHA exposure 
for small children after i.v. ARS.
Exclusion of patients in period two of the crossover trials 
influenced covariate selection and resulted in associations 
between population mean CL and the covariates hemoglobin 
and body temperature. After controlling for body weight, the 
population mean V for men was lower compared to women, 
and lower hemoglobin concentrations and higher body tem-
peratures were associated with reduced DHA exposure 
levels. Sex has also been reported to be associated with 
increased mean CL/F by 1.14-fold for a male compared with 
a female in a population PK study of i.r. ARS in a mixed adult–
pediatric population.23 An explanation for the lack of observed 
association between hemoglobin and temperature with CL 
when patients who received i.v. ARS in the second period 
of the crossover trials are included is that hemoglobin and 
temperature values will have improved from baseline by the 
time these patients receive i.v. ARS in period two of the trial. 
Although the evidence of association was weak, the direction 
of effect between hemoglobin and temperature with CL was 
still the same as that observed in the analysis with period two 
patients excluded, just of a lower magnitude.
We did not observe any relationship between DHA expo-
sure and the parasitological outcomes, parasite clearance 
half-life (determined using the PCEstimator)24 and PC90 
at 12 h. This may be partly due to lack of statistical power. 
These analyses excluded patients who received i.v. ARS in 
the second period of the crossover trial (n = 43) and were 
not given an i.v. ARS dose between 2 and 3 mg/kg (n = 81), 
and patients whose parasitemia vs. time profiles did not allow 
determination of parasite clearance half-life (n = 27) or did 
not have parasitemia recorded 12 h posttreatment (n = 87). 
A lack of correlation between DHA exposure and the para-
sitological outcomes has also been observed for i.m. ARS 
in a pediatric population (also low statistical power, n = 70)7 
and for i.r. ARS in mixed adult–pediatric populations (a larger 
study but very noisy data and sparse sampling).23 The original 
studies included in the pooled analysis were not designed (or 
were underpowered) to detect clinically important changes in 
parasitological outcomes. The power was further reduced by 
the inability to determine parasitological outcomes in all 142 
patients who received 2.4 mg/kg of i.v. ARS at baseline. How-
ever, the estimates in table 4 are consistent with a doubling 
of DHA AUC0–12h and Cmax decreasing the parasite clearance 
half-life by 0.17 h (~10 min) and 0.12 h (~7 min), respectively.
In conclusion, DHA exposure was lower for smaller children 
(6–10 kg) compared with adults. The findings from this pooled 
analysis of severe malaria patients receiving i.v. ARS support 
the dose adaption previously recommended in a separate anal-
ysis of children receiving i.m. ARS. The finding in Hendriksen 
et al.7 and in the current study that DHA exposure is lower in 
smaller children compared to larger children and adults sug-
gests that the current dose may be suboptimal for smaller 
children. We were unable to quantify the clinical importance of 
this finding, but recommend dose finding studies, designed to 
detect clinically important changes in parasitological outcomes, 
should be performed, and the dose adaption proposed in Hen-
driksen et al.7 (and supported by this study) would be a suitable 
candidate for comparison to the current dosing regimen.
MetHODS
Study population, study design, dosing, and sampling
Details of the study population, design, and dosing for each 
of the six studies included in the pooled analysis are provided 
in table 1. The criteria chosen by each study to define severe 
malaria is provided in Supplementary table S2. Patients 
were considered as having moderately severe malaria if 
they did not have any of the features of severe malaria (see 
 Supplementary table S2) and could not be given oral ther-
apy because of nausea, vomiting, or confusion. The blood 
sampling for determination of ARS and DHA concentrations 
and parasite counts is summarized in table 5.
Drug measurements
ARS and DHA plasma concentrations from each study 
were measured by different laboratories using either high- 
performance liquid chromatography with electrochemical 
detection or mass-spectrometry detection (Supplementary 
table S3). The limit of quantification and limit of detection 
varied across the studies where the earlier studies had limit 
of quantifications of 50 ng/ml (limit of detections of 5–20 ng/
ml) compared with around 2 ng/ml (0.3–0.6 ng/ml) in the more 
recent studies (Supplementary table S3).
Statistical analysis
Pharmacokinetic modeling. The analysis focused exclusively 
on the dynamics of DHA concentrations assuming complete 
in vivo conversion of ARS to DHA.18 This was justified since 
the maximum DHA concentrations were observed within min-
utes following ARS dosing. The administered dose of DHA 
(µg) was calculated using the relative difference in molecular 
weights for DHA and ARS: 284/384 (ARS to DHA conver-
sion factor) × ARS dose (µg). Venous plasma concentrations 
were analyzed as natural logarithms using NLME modeling in 
NONMEM version 7.2 (ICON Development Solutions, Ellicott 
City, MD). The proportion of data below the limit of quantifica-
tion is given in Supplementary table S4 and were modeled 
as censored data using the M3 method.32 Model selection 
was based on the OFV and either VPCs33,34 or posterior pre-
dictive checks35 generated from 1,000 simulated replicates of 
the pooled PK data. The bootstrap as implemented in Perl-
speaks-NONMEM36,37 was used to calculate SEs and 95% 
CIs for the estimates of the population PK parameters and 
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interindividual variability. The NONMEM code used to pro-
duce the results in  table 3 is provided in the section "NON-
MEM code: IV-ARS pooled pharmacokinetic analysis" of the 
Supplementary Information.
Between-study variability. A meta-analytic approach was used 
to build the NLME model for the pooled DHA PK profiles. The 
purpose of these separate NLME model analyses was to deter-
mine whether the same structural and error models are suit-
able for each study and period of the crossover trials, and to 
visually compare the population mean PK parameter estimates 
derived for each study using a forest plot (see Supplementary 
 Information 2). Between-study differences were also exam-
ined using NLME models (see  Supplementary Information 3 
and Supplementary table S5).
Stepwise covariate selection. Four subgroup analyses were 
performed because the same set of covariates was not mea-
sured in all studies; the covariates and study populations 
investigated in each subgroup are summarized in table 2, 
and the stepwise covariate model procedure implemented 
in Perl-speaks-NONMEM was used to determine whether 
the covariates listed in table 2 were statistically significantly 
associated with the population PK parameters (see Supple-
mentary Information 4 for more details).
Pharmacodynamic measures. The pharmacodynamic mea-
sures selected a priori were: parasite clearance half-life 
(obtained from WorldWide Antimalarial Resistance Network’s 
online Parasite Clearance Estimator)24 and the binary mea-
sure PC90 at 12 h (i.e., 90% of baseline parasitemia cleared 
at 12 h—yes (1), no (0)). These measures were derived for 
each individual from peripheral blood smears collected every 
4–6 h (see Supplementary table S6 for parasitemia mea-
surement details) and box plots of the baseline parasitemia for 
each study are presented in Supplementary Figure S4. Asso-
ciations between the pharmacodynamic measures and post 
hoc individual estimates of DHA CL, V, AUC, and C
max
 were 
investigated using multivariable linear regression for parasite 
clearance half-life and logistic regression for PC90 at 12 h. The 
post hoc individual estimates of CL, V, AUC, and C
max
 were log2 
transformed and included separately in each regression model. 
All regression analyses were adjusted for age (years), sex 
(male (1); female (0)), weight (kg), and baseline parasitemia 
(log
e
 transformed). These statistical analyses were performed 
using STATA Version 12 (StataCorp, College Station, TX). Sin-
gle mean imputation of the parasite counts at 12 h was per-
formed as follows: step 1, separate linear regressions including 
time as a linear and quadratic variable (i.e., time2) were fitted to 
each patient’s parasite count (log
e
 units) vs. time profile; step 2, 
parasite count at 12 h was imputed using the estimated param-
eters derived in step 1; and step 3, steps 1 and 2 (i.e., imputa-
tion of 12-h parasite count) were only performed for patients 
with at least three parasite counts recorded in the first 24 h, 
including one of these measurements post-12 h.
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Study Highlights
WHAt IS tHe cUrrent KnOWleDge On tHe 
tOPIc?
 3 i.v. ARS reduces risk of death from severe ma-
laria substantially and is the recommended 
treatment for severe malaria in all age groups. 
The current dosing regimen has been largely 
extrapolated from results of studies in adults 
with uncomplicated malaria, and previous stud-
ies of severe malaria were of small sample siz-
es and homogeneous sample populations.
WHAt QUeStIOn DID tHIS StUDY ADDreSS?
 3 We characterize the pharmacokinetic proper-
ties of DHA after i.v. ARS in the largest pooled 
sample of severe malaria patients to date from 
inhomogeneous sample populations. This al-
lows us to address whether the current i.v. ARS 
dosing regimen achieves adequate DHA expo-
sure in both children and adults.
WHAt tHIS StUDY ADDS tO OUr KnOWleDge
 3 Body weight has the greatest impact on the 
pharmacokinetics of DHA and produces lower 
exposure levels in smaller children receiving the 
current i.v. ARS dose of 2.4 mg/kg.
HOW tHIS MIgHt cHAnge clInIcAl 
PHArMAcOlOgY AnD tHerAPeUtIcS
 3 A dose adaption that avoids underdosing in 
smaller children receiving i.m. ARS appears to 
be generalizable to i.v. ARS.
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